688046 Stock Overview
A contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
GemPharmatech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.93 |
| 52 Week High | CN¥20.23 |
| 52 Week Low | CN¥9.08 |
| Beta | 0.47 |
| 1 Month Change | 3.11% |
| 3 Month Change | 25.38% |
| 1 Year Change | -28.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.70% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For GemPharmatech Co., Ltd. (SHSE:688046) Suggests It's 44% Undervalued
Dec 05
GemPharmatech's (SHSE:688046) Problems Go Beyond Weak Profit
Sep 10GemPharmatech (SHSE:688046) Seems To Use Debt Quite Sensibly
Jul 22Some GemPharmatech Co., Ltd. (SHSE:688046) Shareholders Look For Exit As Shares Take 29% Pounding
Apr 16Shareholder Returns
| 688046 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -3.9% | -4.4% | -2.7% |
| 1Y | -28.6% | -17.9% | 11.8% |
Return vs Industry: 688046 underperformed the CN Life Sciences industry which returned -17.9% over the past year.
Return vs Market: 688046 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 688046 volatility | |
|---|---|
| 688046 Average Weekly Movement | 10.0% |
| Life Sciences Industry Average Movement | 10.2% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688046 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688046's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 1,621 | Jing Zhao | www.gempharmatech.com |
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other services.
GemPharmatech Co., Ltd. Fundamentals Summary
| 688046 fundamental statistics | |
|---|---|
| Market cap | CN¥5.75b |
| Earnings (TTM) | CN¥139.41m |
| Revenue (TTM) | CN¥677.34m |
40.8x
P/E Ratio8.4x
P/S RatioIs 688046 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688046 income statement (TTM) | |
|---|---|
| Revenue | CN¥677.34m |
| Cost of Revenue | CN¥247.86m |
| Gross Profit | CN¥429.48m |
| Other Expenses | CN¥290.07m |
| Earnings | CN¥139.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.34 |
| Gross Margin | 63.41% |
| Net Profit Margin | 20.58% |
| Debt/Equity Ratio | 3.2% |
How did 688046 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield56%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 10:43 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GemPharmatech Co., Ltd. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |